Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ: AZN )

65.37 -0.36 (-0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer
From Tempus
Via Business Wire
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum 
Via MarketBeat
AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity
From AstraZeneca
Via Business Wire
Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)
From AstraZeneca
Via Business Wire
Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
From AstraZeneca
Via Business Wire
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022
From AstraZeneca
Via Business Wire
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme
From C4X Discovery Holdings plc
Via GlobeNewswire
AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022
From AstraZeneca
Via Business Wire
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
From Alexion, AstraZeneca Rare Disease
Via Business Wire
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
From AstraZeneca
Via Business Wire
AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
From AstraZeneca
Via Business Wire
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
From AstraZeneca
Via Business Wire
ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
From Alexion
Via Business Wire
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all... 
Via MarketBeat
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer
From AstraZeneca
Via Business Wire
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer
From AstraZeneca
Via Business Wire
AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
From AstraZeneca
Via Business Wire
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
From Ikena Oncology, Inc.
Via GlobeNewswire
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
From Alexion
Via Business Wire
Is Illumina Still the Gamechanger in Genomics Sequencing?
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused 
Via MarketBeat
Topics Earnings Economy Lawsuit
Exposures Financial Legal Supply Chain
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
Exposures COVID-19
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
From Alexion
Via Business Wire
Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis
From Alexion
Via Business Wire
AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
From AstraZeneca
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.